Sisto Margherita, Lisi Sabrina
Department of Translational Biomedicine and Neuroscience (DiBraiN), Section of Human Anatomy and Histology, University of Bari "Aldo Moro", 70124 Bari, Italy.
J Clin Med. 2023 Dec 27;13(1):164. doi: 10.3390/jcm13010164.
Fibrosis is the end result of persistent inflammatory responses induced by a variety of stimuli, including chronic infections, autoimmune reactions, and tissue injury. Fibrotic diseases affect all vital organs and are characterized by a high rate of morbidity and mortality in the developed world. Until recently, there were no approved antifibrotic therapies. In recent years, high levels of interleukin-17 (IL-17) have been associated with chronic inflammatory diseases with fibrotic complications that culminate in organ failure. In this review, we provide an update on the role of IL-17 in fibrotic diseases, with particular attention to the most recent lines of research in the therapeutic field represented by the epigenetic mechanisms that control IL-17 levels in fibrosis. A better knowledge of the IL-17 signaling pathway implications in fibrosis could design new strategies for therapeutic benefits.
纤维化是由多种刺激因素引发的持续性炎症反应的最终结果，这些刺激因素包括慢性感染、自身免疫反应和组织损伤。纤维化疾病影响所有重要器官，在发达国家，其发病率和死亡率很高。直到最近，仍没有获批的抗纤维化疗法。近年来，高水平的白细胞介素-17（IL-17）与伴有纤维化并发症并最终导致器官衰竭的慢性炎症性疾病相关。在本综述中，我们提供了关于IL-17在纤维化疾病中作用的最新情况，特别关注以控制纤维化中IL-17水平的表观遗传机制为代表的治疗领域的最新研究方向。更好地了解IL-17信号通路在纤维化中的影响，可为设计新的治疗策略提供依据。
